Factor B is a serine protease, essential for the function of the alternative pathway of complement activation. To study further the importance of the alternative pathway of complement activation in vivo and to help elucidate any additional functions of factor B or its activation fragments we developed, by homologous recombination in embryonic stem cells, mice with a disrupted factor B gene. Factor B-deficient mice produced no detectable factor B mRNA or protein and had no detectable factor B enzymatic activity or alternative pathway function in their serum. Further studies revealed that the two adjacent genes, complement component C2 and D17H6S45, had been down regulated as a result of the disruption. The down-regulation of C2 gene expression was sufficient to cause a complete loss of classical pathway function as determined by the failure of sera from the deficient mice to opsonize antibody-sensitized sheep erythrocytes and by impairment of immune complex processing in vivo. The resulting mouse is deficient in both factor B and C2, and hence the alternative and classical pathways of complement activation, and adds to the repertoire of models for studying the in vivo role of complement in the immune system.
Factor B is a serine protease, essential for the function of the alternative pathway of complement activation. To study further the importance of the alternative pathway of complement activation in vivo and to help elucidate any additional functions of factor B or its activation fragments we developed, by homologous recombination in embryonic stem cells, mice with a disrupted factor B gene. Factor B-deficient mice produced no detectable factor B mRNA or protein and had no detectable factor B enzymatic activity or alternative pathway function in their serum. Further studies revealed that the two adjacent genes, complement component C2 and D17H6S45, had been down regulated as a result of the disruption. The down-regulation of C2 gene expression was sufficient to cause a complete loss of classical pathway function as determined by the failure of sera from the deficient mice to opsonize antibody-sensitized sheep erythrocytes and by impairment of immune complex processing in vivo. The resulting mouse is deficient in both factor B and C2, and hence the alternative and classical pathways of complement activation, and adds to the repertoire of models for studying the in vivo role of complement in the immune system.
The alternative pathway (AP) 1 of complement activation forms an ancient part of the innate immune system (1) . The primary role of the AP probably lies in the immediate response to local infection by extracellular pathogens and can proceed on many microbial surfaces in the absence of specific antibody. The AP is also activated after C3b deposition by the classical pathway of complement activation and serves to amplify the classical pathway response by depositing more C3b on the surface of immune complexes.
Factor B is a serine protease that, in conjunction with C3b activated by the serine protease factor D, forms the C3/C5-convertase of the AP. Activation by factor D cleaves factor B into Ba, a small peptide released into the fluid phase, and Bb, which contains the serine protease domain and remains associated with C3b in the C3/C5-convertase. The murine factor B gene (H2-Bf) is located in the S region of the major histocompatibility complex class III region (2) . The gene lies directly adjacent to the gene for complement component C2, the polyadenylation signal of C2 overlapping with the 5Ј-regulatory region of H2-Bf (3, 4) . The 3Ј-untranslated region of H2-Bf overlaps with the 3Ј-untranslated region of the D17H6S45 gene (5), a gene with an unusual periodic structure and no defined function, formerly known as Rd (6) . Factor B is primarily synthesized in the liver (7) and has been shown to be produced by hepatocytes (8) and a wide variety of extrahepatic cells, including mononuclear phagocytes (9, 10), fibroblasts (11) , and epithelial and endothelial cells (12, 13) . As well as being an essential component of the AP C3/C5-convertase there has also been some evidence that the activation fragments of factor B may have roles as B cell growth factors (14, 15) , stimulants of mononuclear cell cytotoxicty (16, 17) , inducers of macrophage spreading (18) , and immunosuppressants (19) .
Deficiencies of components of the AP are extremely rare, and those that have been described presented in patients with very severe neisserial infections. The first factor B deficiency has only very recently been described in a 6-year-old boy who presented with a very severe meningococcal infection, an antigenically abnormal factor B protein, and no detectable factor B functional activity (20) . In contrast, deficiencies of the classical pathway components are more common than those of the alternative pathway, and studies of humans with classical pathway component deficiencies have greatly increased our understanding of the roles of complement in vivo. Early classical pathway component deficiencies are strongly associated with immune complex-mediated diseases such as systemic lupus erythematosus. Complement-deficient humans (21) , and more recently a genetically engineered model of classical pathway deficiency, a C1q-deficient mouse (22) , have both been demonstrated to have abnormal immune complex processing.
To further our understanding of the physiological roles of the alternative pathway and factor B in vivo, we generated by homologous recombination in embryonic stem (ES) cells a mouse deficient in factor B by replacing exons 1 to 18 of the gene with a promoterless lacZ reporter gene and the neomycin resistance gene. H2-Bf-deficient mice are fully viable when kept under specific pathogen-free conditions, and the disrupted allele was inherited in accordance with normal Mendelian patterns. The mice showed no gross phenotypic abnormalities; however, we found that the expression of the two neighboring genes, C2 and D17H6S45, was reduced and that the mice were functionally deficient in the classical as well as the alternative pathway.
EXPERIMENTAL PROCEDURES

Generation of Mice Deficient of Complement Factor B
Mice with a disrupted H2-Bf locus were generated by homologous recombination in ES cells (23) (Fig. 1A) . The targeting vector pH2-Bf.lacZ/neo-HSVtk was constructed using isogenic DNA isolated from a 129/Sv genomic DNA library (Stratagene). All of the exons of H2-Bf from 1 to 18 (the last) corresponding to amino acids 4 onward and encompassing approximately 6 kb of genomic DNA were replaced with a 4.6-kb cassette consisting of a promoterless lacZ reporter gene linked to a positively selectable marker, the neomycin resistance gene (neo) under the control of the pMC1 promoter. The lacZ/neo cassette was flanked on the 5Ј side by a 4.6-kb region of genomic DNA from exon 9 of C2 to exon 1 of H2-Bf and on the 3Ј side by a 2.8-kb genomic fragment from exon 18 of H2-Bf to exon 7 of the D17H6S45 gene. External to the 5Ј region of homology with the target locus was placed a negatively selectable marker gene, the herpes simplex virus thymidine kinase gene (HSVtk). ES cells were transfected by electroporation with the linearized targeting vector pH2-Bf.lacZ/neo-HSVtk. Colonies surviving positive/negative selection (24) were isolated and screened by Southern blot (25) of EcoRI-digested genomic DNA using a 3Ј-external probe (P1) (Fig. 1B) . After identification of clones with a disrupted H2-Bf gene a 5Ј-external probe (P2) was used to confirm that genuine homologous recombination had occurred on both sides of the gene. A third probe within the targeting vector was used to confirm that the clones contained only the single copy of the targeting vector. Recombinant clones were microinjected into 3.5-day postcoitus blastocysts of C57BL/6 mice. The chimeric mice generated were bred with female C57BL/6 mice, and germline transmission was detected by the presence of agouti offspring, which were screened for the disrupted allele.
All experimental animals were adults (between 8 and 12 weeks of age) and of a mixed genetic background, (129/Sv ϫ C57BL/6) F 2 . Wild type (H2-Bfϩ/ϩ) and heterozygous (H2-Bfϩ/Ϫ) littermates matched for sex and age were used as controls for H2-Bf-deficient (H2-BfϪ/Ϫ) mice. For all in vitro hemolytic assays, male mice were used. When serum was required, blood samples were taken and left to coagulate on ice; the serum was used the same day and was kept on ice at all times.
mRNA Analysis
Total RNA was extracted from liver using guanidinium thiocyanateCsCl density gradient centrifugation (25) . Total RNA was electrophoresed in 0.8% agarose 2.2 M formaldehyde gels and Northern blotted onto Hybond Nϩ (Amersham International, Buckinghamshire, UK) nylon membranes. First strand cDNA synthesis was undertaken using Superscript reverse transcriptase (Life Technologies, Inc.) as directed by the manufacturer. For amplification of the C2 cDNA the primers C2/10 (5Ј-CATCTATGCTATTGGGGTGG-3Ј) and C2/13b (5Ј-CCGAGATAG-CTTCAGCAAGGC-3Ј) were used to generate a product of 492 bp. The 5Ј-untranslated region of H2-Bf cDNA was amplified with the primers Bf/5Ј (5Ј-TGTAGCCAGATCCAGCATTTG-3Ј) and Bf/1b (5Ј-TCTCCAT-TGTCATGGAAAGC-3Ј), producing a 118-bp product. D17H6S45 cDNA was amplified with the primers Rd/8ϩ (5Ј-GAACACACTGTATGTG-TATGG-3Ј) and Rd/10Ϫ (5Ј-CAAGGGAGCCCCAGACAGATT-3Ј), yielding a 262-bp product. The cDNA from the gene for complement component C4 (C4) was amplified with the primers C4/2ϩ (5Ј-GAAGGACT-TTAAGCTGAGCTC-3Ј) and C4/3Ϫ (5Ј-CTGAGCTACCAGCTGGATG-TG-3Ј), resulting in a 129-bp product. Control primers for the amplification of the C1qA gene that generated a fragment of 339 bp were: C1qAI/1 (5Ј-TGGACAGTGGCTGAAGATGTC-3Ј) and C1qAII/1 (5Ј-AT-AACCACGTTGCCAAGCGCT-3Ј). The cDNA of C2, D17H6S45, C4, C1qA, and H2-Bf were amplified under the same conditions (1 unit of BIOTaq DNA polymerase (Bioline UK Ltd.), 2.5 mM Mg 2ϩ , 0.2 mM dNTPs) using 20, 25, and 30 thermocycles, to give an estimation of the relative quantities of message present, each one being co-amplified with the C1qA gene to control for variability in the cDNA synthesis and PCR reactions.
Hemolytic Assays
Functional Factor B Activity-A previously described in vitro assay with a trypsin-activated cobra venom factor-dependent convertase com- plex was used to detect functional factor B activity in mouse serum (26) . In brief, 20 l of 10% v/v mouse serum was incubated with 10 l of 100 units/ml cobra venom factor (a kind gift from M. B. Pepys, Immunological Medicine, Imperial College School of Medicine), in the presence of 1 mM Mg 2ϩ , at 37°C for 10 min and activated by incubation with 10 l of 1 mg/ml bovine trypsin (Sigma-Aldrich, Poole, UK). The trypsin was inhibited with 10 l of 2.5 mg/ml soybean trypsin inhibitor (SigmaAldrich), and the late components of complement were provided by the addition of 50 l of 10 mM EDTA/normal human serum. Guinea pig erythrocytes (2 ϫ 10 8 cells in 50 l) were added and incubated at 37°C for 90 min. The reaction was quenched by the addition of 1 ml of ice-cold PBS, and the amount of lysis was determined by the absorption at 413 nm of the supernatant after centrifugation at 10,000 ϫ g for 1 min.
Total Hemolytic Activity-The classical pathway mediated total hemolytic complement activity in mouse serum was determined by release of 51 Cr-labeled hemoglobin from antibody-sensitized sheep erythrocytes as described previously (27) .
Alternative Pathway Hemolytic Activity-The protocol for the alternative pathway hemolytic assay was the same as the total hemolytic activity assay except that a 5% v/v suspension of guinea pig erythrocytes in PBS, 0.007 M Mg 2ϩ , 0.01 M EGTA (pH 7.2) was used instead of sensitized sheep erythrocytes, and the serum was preincubated in PBS, 0.007 M Mg 2ϩ , 0.01 M EGTA (pH 7.2) to make the hemolytic assay specific for the alternative pathway.
C3 Opsonization Assay
Sheep erythrocytes were sensitized with a subagglutinating titer of rabbit hemolytic serum (TCS, Buckinghamshire, UK). 100 l of cells at a concentration of 5 ϫ 10 8 cells/ml were incubated for 15 min at 37°C with 100 l of mouse serum diluted 1:5 in PBS, 1% bovine serum albumin. The cells were pelleted by microfugation at 10,000 ϫ g for 1 min, and the supernatant was removed. Fluid phase C3 was removed by repeated washing of the cells with ice-cold PBS, 1% bovine serum albumin. The cell pellet was resuspended in a final volume of 200 l, and 50 l were added of a 20 g/ml suspension of a 125 I-radiolabeled rat IgG2a monoclonal antibody against murine C3 (Connex, Martinsreid, Germany). The anti-C3 monoclonal antibody was radiolabeled by the direct IODO-GEN method (28) to a specific activity of 18.5 MBq/mg. After incubation for 30 min at 37°C with frequent agitation, two 75-l aliquots of the cell suspension were removed and spun through 150 l of di-"isononyl" phthalate oil (Fluka Chemicals, Gillingham, UK) at 10,000 ϫ g for 5 min. The tubes were cut, and the radioactivity of the cell pellet was used to determine the number of molecules of anti-C3 monoclonal present as a measure of C3 molecules bound per erythrocyte. Serum treated with EDTA to a concentration of 50 mM was used as a negative control, and serum treated with PBS, 0.007 M Mg 2ϩ , 0.01 M EGTA was used as a control for AP activity.
Immune Complex Processing
Heat-aggregated murine IgG (HAGG) was used as a model immune complex. HAGG was prepared by incubation of total murine IgG (Sigma-Aldrich), at a concentration of 10 mg/ml, at 56°C for 30 min, and insoluble complexes were removed by centrifugation at 1,100 ϫ g for 10 min. The HAGG was then radiolabeled by the direct IODO-GEN method (28) to a specific activity of 37 MBq/mg. H2-Bf-deficient animals and their wild type and heterozygous littermates were injected intravenously with 1 g of 125 I-labeled HAGG (equivalent to 37 kBq of radioactivity). HAGG was injected with an equal volume of a 10% suspension of 51 Cr-labeled mouse erythrocytes as a blood pool tracer to control for injection quality. The mouse red blood cells were labeled by incubating 4 ml of a 10% suspension in PBS with 7.4 MBq of 51 Cr for 60 min at 37°C. The cells were washed several times with PBS after labeling to remove unbound radioactivity. Two hours after the injection the mice were killed, a 50-l blood sample was taken, and the spleen and liver were removed and weighed.
125 I and 51 Cr radioactivity was determined using a ␥-scintillation counter and corrected for emission window overlap. The unbound radioactivity present in the intravascular compartment of the spleen was determined from the published murine splenic blood volume of 180 l/g (29) , and the 125 I-HAGG was measured in a unit blood volume. Immune complex uptake was defined as: ( 125 I cpm of the whole organ Ϫ 125 I cpm in blood pool of the organ)/ organ mass. Analysis of the 51 Cr radioactivity in the blood sample confirmed consistency in injection quality. All methods used to calculate the organ distribution of the HAGG, including percentage of injected HAGG in the organ, counts/min/g of organ mass and counts/min of the whole organ gave consistent results, whether corrections were made for blood pooling effects or not.
RESULTS
The murine H2-Bf gene was disrupted in ES cells by homologous recombination with the targeting vector pH2-Bf.lacZ/ neo-HSVtk. A targeting frequency of approximately 1 in 16 of the double selection resistant ES cell clones was achieved at the H2-Bf locus. Five of the recombinant clones were chosen, determined to have a euploid karyotype, and microinjected into 3.5-day postcoitus blastocysts of C57BL/6 mice. Four of the five clones generated chimeras that transmitted the disrupted allele through the germline. Four independent lines of H2-Bfdeficient animals (Bf-16, Bf-40, Bf-79, and Bf-114) were established in both the mixed (129/Sv ϫ C57BL/6) and pure (129/Sv) genetic backgrounds. H2-Bf-deficient mice had neither detectable factor B mRNA by Northern blot (Fig. 2) , using a cDNA probe that encodes the Ba activation fragment, nor protein in their serum by radial-immunodiffusion using a cross-reacting rabbit anti-human factor B polyclonal antisera (Calbiochem, Nottingham, UK). H2-Bf-deficient animals showed no specific functional factor B activity in the cobra venom factor-dependent assay (data not shown) and no detectable alternative pathway activity as demonstrated by their failure to lyse guinea pig erythrocytes (data not shown). The mice were fully viable under specific pathogen-free conditions, and the disrupted allele was inherited in accordance with normal Mendelian inheritance patterns (the genotypes of 296 offspring from F 1 heterozygous crosses were 77 H2-BfϪ/Ϫ (26%), 146 H2-Bfϩ/Ϫ (49.3%), and 73 H2-Bfϩ/ϩ (24.7%)).
Northern blot analysis of the neighboring gene for complement component C2 failed to detect C2 mRNA in liver RNA of H2-Bf-deficient mice (Fig. 2) , while the transcript was visible in the wild type mice. Overexposure of the same film showed a very weak signal of the correct size in the gene-targeted mice (data not shown). To better quantify the C2 mRNA present, a semiquantitative RT-PCR was used. C2 cDNA was amplified at the same time as cDNA for the C1qA gene using 20, 25, and 30 cycles. C2 product was not detectable after 20 amplification cycles in the deficient mice, whereas it was already visible in the wild type littermates (Fig. 3) . After 25 cycles, the message was detected in the deficient mice, but the product was much more abundant in the wild type mice. Amplification of the C1qA gene was equivalent at all steps between all mice. This RT-PCR observation is consistent with the presence of C2 mRNA, albeit at greatly reduced levels. The 5Ј-untranslated region of the H2-Bf gene was amplified in the same way, since this region of the mRNA should be retained in the deficient mice where only the H2-Bf coding sequence was replaced by the lacZ reporter gene. The results obtained by RT-PCR were very similar to those for C2 (Fig. 3) . The 5Ј-untranslated region was not visible after 20 cycles of amplification in the deficient animals, whereas it could be seen in the wild type mice. After 25 cycles, the product was detectable from the deficient mice but again at much reduced levels compared with the wild type. Amplification of the C1qA cDNA was equal between deficient and sufficient mice. This latter observation suggests that the reporter gene was expressed at much lower levels than the wild type H2-Bf gene. This observation could not be confirmed by direct comparison on Northern blot as the 5Ј-untranslated region of H2-Bf did not work successfully as a probe. A similar pattern of gene expression was observed for the downstream neighbor gene of H2-Bf, D17H6S45 (Fig. 3) . Expression of the gene for complement component C4 (C4) was checked to determine if the effect of the gene targeting was localized to these three genes or if it had spread further, since C4 is approximately 40 kb downstream of H2-Bf. The expression of C4 was found to be similar in H2-Bf-deficient and -sufficient mice (Fig. 3) , suggesting that the effects of the gene-targeting event were localized.
In the absence of an antigenic assay for mouse C2 we assessed the classical pathway-mediated total hemolytic complement activity in the serum. The percentage of total lysis (ϮS.E.) caused by serum from H2-Bfϩ/ϩ (n ϭ 5) and H2-Bfϩ/Ϫ (n ϭ 5) mice was 49.3% (Ϯ8.13%) and 45.8% (Ϯ10.24%), respectively. The H2-BfϪ/Ϫ (n ϭ 5) mice were unable to lyse antibody-sensitized sheep erythrocytes (0.85 Ϯ 0.37%). As a further test of the classical pathway activity, we measured the ability of the serum from the deficient animals to opsonize antibodysensitized sheep erythrocytes with C3 and found that this was also absent (Fig. 4) and no different to the opsonizing capabilities of serum from C1q-deficient mice, which are specifically deficient of the classical pathway of complement activation. Serum from normal mice was able to bind nearly 1700 molecules of C3 per erythrocyte. The alternative pathway alone was unable to opsonize the antibody-sensitized erythrocytes, demonstrating the specific requirement for the classical pathway. To further confirm the total absence of classical pathway activity in these mice, we decided to evaluate immune complex processing in vivo. Immune complex processing has previously been shown to be abnormal in humans with classical pathway deficiency (21) and also in C1q-deficient mice (22) . Splenic uptake of radiolabeled heat-aggregated murine IgG was severely impaired in the H2-Bf-deficient mice (Fig. 5A) . The difference in splenic uptake was analyzed using the MannWhitney U test. Two hours postinjection the median splenic uptake of HAGG was 23,180 cpm/g (range 12,380 -30,350) in 10 gene-targeted mice, compared with 42,040 cpm/g (range 31,940 -103,300) in 13 control mice (U ϭ 0, p Ͻ 0.0001). Hepatic uptake in the H2-Bf-deficient mice was no different from the controls (Fig. 5B) . The median hepatic uptake in the 10 H2-Bf-deficient mice was 35,460 cpm/g (range 20,510 -49,390), compared with 27,680 cpm/g (range 10,450 -64,320) in the 13 control mice (U ϭ 53, p Ͻ 0.48). The organ distribution of the aggregated IgG was no different form that observed in C1q-deficient mice (data not shown). Splenic uptake of monomeric murine IgG was approximately 40% of the uptake of HAGG in the complement-deficient animals (data not shown), implying that very little splenic uptake of aggregates was occurring in the deficient animals. These results suggest an effective total failure of classical pathway activity in vivo.
DISCUSSION
Here we report a characterized total deficiency of complement component factor B. Mice were generated by homologous FIG. 3 . Semiquantitaive RT-PCR analysis of C2, D17H6S45, lacZ, and C4 expression in H2-Bf؊/؊ mice. C2, lacZ, D17H6S45, and C4 transcripts were amplified from liver cDNA in conjunction with C1qA cDNA. Different cycle numbers were used for estimation of the relative levels of the cDNA present. In all of the PCR reactions the C1qA cDNA was amplified equally well from gene targeted and wild type mice. C2, lacZ, and D17H6S45 products were not detectable after 20 cycles in the targeted mice, but they were visible in the wild type mice. C2, lacZ, and D17H6S45 RT-PCR products became visible in the deficient mice after 25 cycles, but the product were much more abundant in the wild type mice. C4 gene expression was equivalent between genetargeted and control mice. recombination in ES cells that carried a disrupted H2-Bf allele with the entire coding region of the wild type gene replaced with a promoterless lacZ reporter gene cloned into the same reading frame as the first codons of H2-Bf. Downstream of the lacZ gene was the positively selectable marker gene for neomycin resistance. Four independent ES cell clones generated lines of mice carrying the disrupted gene. Homozygous H2-Bfdeficient animals had no detectable levels of factor B in their serum by radial immunodiffusion and had no specific functional factor B activity in a cobra venom factor-dependent assay. H2-Bf-deficient animals had no AP activity demonstrated by their failure to lyse guinea pig erythrocytes. The mice were fully viable under specific pathogen-free conditions. In all four different lines of H2-Bf-deficient mice, transmission of the targeted allele was in accordance with normal Mendelian inheritance. This observation is not entirely in agreement with that of Matsumoto et al. (30) , who have recently generated H2-Bfdeficient mice and found a selective disadvantage for the inheritance of their disrupted factor B allele in only one of their two mouse lines. This abnormal inheritance pattern may have been due to chance. Surprisingly, the mutation introduced into the H2-Bf gene caused a dramatic down-regulation in the expression of the neighboring gene for complement component C2 of the classical pathway. The regulatory elements of C2 expression reported in the literature are 5Ј of C2, away from the site of the deletion (31) , and at the 3Ј end of the gene in the intragenic region between H2-Bf and C2 (32) (33) (34) unaffected by the targeting event. Expression of a second neighboring gene, D17H6S45, was similarly affected by the targeting event. There are four possible explanations for the observed phenomenon. (i) Regulatory elements for C2, D17H6S45, and lacZ expression present within the factor B gene were deleted in the gene-targeting vector. This hypothesis would require the loss of a common regulatory element for all three genes, or conceivably, three independent elements located in the same region (downstream of C2 and D17H6S45 and internal to the factor B gene). (ii) A mutation has been introduced into either or both of the C2 or D17H6S45 genes by the process of homologous recombination. It is unlikely that the targeting vector carried a mutation, since the coding regions of both the C2 and D17H6S45 genes contained within the vector were sequenced before transfection. It is also very unlikely that the actual integration of the vector caused independent mutations with identical effects, since mice were generated from four independently targeted embryonic stem cell clones, and all four lines exhibited no classical pathway activity and showed reduced D17H6S45 expression. (iii) The presence of the neomycin resistance gene in the target gene has interfered with local gene expression. Retention of the selection cassette after homologous recombination is now accepted to have the potential to influence the expression of neighboring genes. Targeted disruption of the 5Ј DNase hypersensitive site 2 of the murine ␤-globin locus control region with PGKneo (neomycin resistance gene driven by the phosphoglycerate kinase promoter) caused a 2-5-fold reduction in the expression of all the genes of the locus. However, after removal of the selection cassette using the FLP recombinase, the expression returned to near normal levels (35) , demonstrating that the effect was due to the introduction of the selection cassette, possibly as a result of the phosphoglycerate kinase promoter competing with the promoters of the ␤-like globin genes for the locus control region. Other examples of potential interference by the selection cassette have been reported after targeted deletions of the myogenic gene MRF4 and of the Hox genes (reviewed in Olson et al. (36) ), and of the Ig light chain intronic enhancer/matrix attachment region (37) . Furthermore, the introduction of a selection cassette upstream and in the same orientation of another gene could cause transcriptional interference (38) . However, this could not be the explanation for the down-regulation of C2 or D17H6S45, since the selection cassette is downstream of C2 and in the opposite orientation to D17H6S45. The explanation of promoter competition for our findings seems unlikely for two other reasons. H2-Bf locus has become subject to gene silencing affecting the expression of C2 and D17H6S45. Position-dependent expression of transgenes has been reported in mice (39) and is thought to be due to the ability of the integration site to repress expression. The same lacZ/neo cassette that we have used here has been reported to give appropriate tissue-specific expression in other gene-targeted mice (40) . It has been suggested that the presence or lack of sequences within lacZ may interfere with the chromatin structure (41) , indicating the possibility that the lacZ cassette may intefere with gene expression. Other transgenic studies have shown that the introduction of mammalian cDNAs or prokaryotic reporter genes, such as lacZ, downstream of a transgene can reduce its expression (42) . This may be due to the absence of introns in the cDNAs and prokaryotic genes. Introns have been shown to enhance the efficiency of expression of a transgene (43) and for this reason are generally incorporated into transgenic experiments. Introns have also been demonstrated to stimulate nucleosome alignment directly affecting chromatin structure (44) . It is possible that the intronless lacZ gene, downstream of the C2 and D17H6S45 gene loci, serves as an active focus for gene silencing in the same manner as that observed with mammalian cDNAs and prokaryotic reporter genes in transgenic experiments by altering the chromatin structure. This silencing could then spread to the flanking genomic sequences affecting C2 and D17H6S45 expression. The observation that C4 expression is conserved in the gene-targeted mice suggests that, if this is a gene silencing effect, it is localized to the immediate neighbors of H2-Bf.
Recently attention has focused on the influence that a selectable marker has on local gene expression (35) (36) (37) . A common response to this problem is to use the FLP or Cre (45, 46) recombinase systems to remove the selectable marker after gene targeting has been achieved. In this instance we wished to leave a reporter gene under the control of the H2-Bf promoter to be able to follow gene expression during embryonic development in case the deficiency was lethal. The effects on the neighboring genes observed here are quite dramatic and emphasize the need for caution in gene-targeting experiments, even if the neighboring genes function is unknown or considered "irrelevant" to the aim of the work.
A challenging question raised by these findings concerns the function of the D17H6S45 gene. It encodes a protein with a very unusual region of precise RD dipeptide repeats that exhibits a very high degree of conservation between man and mouse (47, 48) . The sequence similarity between this protein and other proteins involved in splicing (47) and the fact that a family of RD proteins have been localized to the spliceosomal complexes (49) are suggestive of a role in splicing. The strong evolutionary conservation and proposed biological function of D17H6S45 indicates that its RD protein may have an important if not essential role. The gene-targeted mice described here have severely reduced levels of expression of D17H6S45. Whether these reduced levels of D17H6S45 expression will help elucidate the functions of the RD protein remains to be investigated.
In the absence of a direct antigenic assay for murine C2 we pursued assays of mouse classical pathway activity both in vitro and in vivo to demonstrate the nature of the C2 deficiency. In vitro, serum from these factor B-deficient mice was unable to lyse antibody-sensitized sheep erythrocytes, or to opsonize these cells with C3. In vivo, these animals had defective splenic uptake of immune complexes equivalent to that which we observed in C1q-deficient mice (22) . With respect to the complement status of these mice, we reached the conclusion that these mice are functionally deficient of both the alternative and classical pathways of complement activation. These complementdeficient mice will provide a valuable model for exploring in vivo the role of the complement system and factor B in the immune system.
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